{"disease":{"id":"metastasis-from-malignant-tumor-of-colon","name":"Metastasis from malignant tumor of colon","therapeutic_area":"","data":{},"enrichment_level":0,"last_enriched_at":null,"visit_count":0,"created_at":"2026-04-19T18:31:21.150Z","updated_at":"2026-04-19T18:39:44.960Z","meddra_pt":null,"meddra_code":null,"icd10_codes":null,"synonyms":[],"prevalence_global":null,"prevalence_us":null,"marketed_drug_count":11,"pipeline_drug_count":0,"trial_count":0},"drugs":{"marketed":[{"drug_id":"aflibercept","indication_name":"Metastasis from malignant tumor of colon","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Vegf Trap","generic_name":"AFLIBERCEPT","company_name":"Regeneron","drug_phase":"marketed","molecular_target":"Vascular endothelial growth factor A","drug_class":"Vascular Endothelial Growth Factor Inhibitor","quality_score":55,"revenue":"9800","mechanism":""},{"drug_id":"regorafenib","indication_name":"Metastasis from malignant tumor of colon","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Stivarga","generic_name":"regorafenib","company_name":"Bayer","drug_phase":"marketed","molecular_target":"Bifunctional epoxide hydrolase 2","drug_class":"Kinase Inhibitor","quality_score":86,"revenue":"400","mechanism":"Stivarga blocks the activity of enzymes involved in tumor growth and angiogenesis."},{"drug_id":"oxaliplatin","indication_name":"Metastasis from malignant tumor of colon","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Eloxatin","generic_name":"Oxaliplatin","company_name":"Yakult Honsha","drug_phase":"marketed","molecular_target":"DNA","drug_class":"Platinum-based chemotherapy agent","quality_score":70,"revenue":null,"mechanism":"Oxaliplatin forms platinum-DNA crosslinks that inhibit replication and transcription."},{"drug_id":"eylea","indication_name":"Metastasis from malignant tumor of colon","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Eylea","company_name":"Texas Retina Associates","drug_phase":"marketed","molecular_target":"Placenta growth factor, Vascular endothelial growth factor A, Vascular endothelial growth factor B","drug_class":"","quality_score":16,"revenue":null,"mechanism":null},{"drug_id":"irinotecan","indication_name":"Metastasis from malignant tumor of colon","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Camptosar","generic_name":"irinotecan","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"topoisomerase I","drug_class":"Topoisomerase Inhibitor","quality_score":76,"revenue":null,"mechanism":"Irinotecan and its metabolite SN-38 bind to the topoisomerase I-DNA complex, preventing DNA repair and causing double-strand breaks."},{"drug_id":"fluorouracil","indication_name":"Metastasis from malignant tumor of colon","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Carac","generic_name":"fluorouracil","company_name":"Extrovis","drug_phase":"marketed","molecular_target":"Aromatase","drug_class":"Nucleoside Metabolic Inhibitor [EPC]","quality_score":65,"revenue":null,"mechanism":""},{"drug_id":"irinotecan-hydrochloride","indication_name":"Metastasis from malignant tumor of colon","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Camptosar","generic_name":"Irinotecan Hydrochloride","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Acetylcholinesterase","drug_class":"Topoisomerase Inhibitor","quality_score":79,"revenue":null,"mechanism":"Camptosar works by blocking the enzyme topoisomerase I, which is necessary for DNA replication, thereby preventing cancer cells from dividing and growing."},{"drug_id":"onivyde","indication_name":"Metastasis from malignant tumor of colon","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Camptosar","generic_name":"onivyde","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Acetylcholinesterase","drug_class":"Topoisomerase Inhibitor","quality_score":74,"revenue":null,"mechanism":"Camptosar works by inhibiting topoisomerase I, an enzyme that helps DNA replicate, causing DNA damage and cancer cell death."},{"drug_id":"5-fu","indication_name":"Metastasis from malignant tumor of colon","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Carac","generic_name":"5-fu","company_name":"Spectrum Pharms","drug_phase":"marketed","molecular_target":"Aromatase","drug_class":"Nucleoside Metabolic Inhibitor","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"xeloda","indication_name":"Metastasis from malignant tumor of colon","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Xeloda","company_name":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","drug_phase":"marketed","molecular_target":"Thymidylate synthase","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"capecitabine","indication_name":"Metastasis from malignant tumor of colon","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Xeloda","generic_name":"capecitabine","company_name":"Cheplapharm","drug_phase":"marketed","molecular_target":"Thymidylate synthase","drug_class":"Nucleoside Metabolic Inhibitor [EPC]","quality_score":67,"revenue":null,"mechanism":"Xeloda works by inhibiting the enzyme thymidylate synthase, which is necessary for DNA synthesis in cancer cells."}],"pipeline":[],"offLabel":[],"totalMarketed":11,"totalPipeline":0},"trials":{"data":[],"total":0},"guidelines":[{"drug_id":"irinotecan-hydrochloride","guideline_body":"FDA label","recommendation":"Irinotecan hydrochloride injection is indicated for patients with metastatic carcinoma of the colon or rectum whose disease has recurred or progressed following initial fluorouracil-based therapy.","line_of_therapy":"2L","evidence_grade":"not specified","guideline_year":null},{"drug_id":"regorafenib","guideline_body":"FDA label","recommendation":"STIVARGA is indicated for the treatment of adult patients with metastatic colorectal cancer (CRC) who have been previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, an anti-VEGF therapy, and, if RAS wild-type, an anti-EGFR therapy.","line_of_therapy":"3L+","evidence_grade":"Not specified","guideline_year":null},{"drug_id":"regorafenib","guideline_body":"FDA label","recommendation":"STIVARGA is indicated for the treatment of adult patients with locally advanced, unresectable or metastatic gastrointestinal stromal tumor (GIST) who have been previously treated with imatinib mesylate and sunitinib malate.","line_of_therapy":"3L+","evidence_grade":"Not specified","guideline_year":null},{"drug_id":"regorafenib","guideline_body":"FDA label","recommendation":"STIVARGA is indicated for the treatment of adult patients with hepatocellular carcinoma (HCC) who have been previously treated with sorafenib.","line_of_therapy":"2L","evidence_grade":"Not specified","guideline_year":null}],"source":"Drug Landscape verified database"}